Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
4.015
+0.435 (12.15%)
At close: Nov 17, 2026, 4:00 PM EST
4.020
+0.005 (0.12%)
Pre-market: Nov 18, 2026, 5:14 AM EST
← View all transcripts

Guggenheim 3rd Annual Healthcare Innovation Conference

Nov 9, 2026

Summary

Phase III is complete for congenital disease, with tumor top-line results expected soon. Plans target a congenital BLA next year, while market estimates total ~6,000 patients and a $5B+ opportunity.

Debjit Chattopadhyay
Company Representative, Guggenheim

All right. Good morning, and thank you for joining Guggenheim's 3rd Annual Healthcare Innovation Conference. I am Debjit, and joining us today are Nevan Elam, Founder and Chief Executive Officer of Rezolute, and Sunil Karnawat, its Chief Commercial Officer. Thank you, and good morning, both of you. Nevan, let me start it off with you. If there are new folks to the story, could you give a real brief introduction, and then we'll kick it off?

Nevan Elam
Founder and CEO, Rezolute

Sure. Happy to do so, Debjit. Thanks again for having us. I think the brief introduction to our story is that we are a late-stage ultra-rare disease company, in the metabolic space, focused on treating refractory hypoglycemia associated with hyperinsulinism. In that space, we have two programs, one for congenital hyperinsulinism and the other for tumor-associated hyperinsulinism. Our therapy is a fully human monoclonal antibody that is designed as the first therapy to treat all forms of hyperinsulinism. While we're focused initially on tumor and on congenital forms of hyperinsulinism, we believe that our antibody's effective across the range and spectrum of all forms of refractory hypoglycemia associated with hyperinsulinism. That includes things like post-surgery, GI surgery.

Really happy and excited that we've completed phase III for the congenital indication, and that we are now on the cusp of actually announcing top-line results for phase III for the tumor indication.

Debjit Chattopadhyay
Company Representative, Guggenheim

Well, thank you for that. Since we have Dr. K on the stage, I'm going to get to the commercial side a little later.

Nevan Elam
Founder and CEO, Rezolute

Sure.

Debjit Chattopadhyay
Company Representative, Guggenheim

But let's talk about the two sort of regulatory questions that we field all the time. Number one being, do you think upLIFT, a single-arm open-label study, would be sufficient for the FDA to approve on the THI indication?

Nevan Elam
Founder and CEO, Rezolute

Absolutely. The short answer is, and I think this speaks volumes to, we can talk a lot about the FDA and talk a lot about public health and talk a lot about rare disease. For the tumor indication, to level set for everyone, especially those who are new to the story, we're talking about often patients who are suffering with malignant tumors and who have entered and exited the hospital multiple times because of their hypoglycemia, because their tumor is over-stimulating the insulin receptor, and their hypoglycemia prevents their ability to take radioactive label therapies like Lutathera. They've been either surgery eligible or non-surgery eligible, and unfortunately, as their hypoglycemia progresses, it can often lead to a state where nothing can be done for weeks or months other than an IV glucose drip and then eventually hospice.

What we've seen as we've been treating patients now for three years through our expanded access program is, as we have worked with the FDA, because every single time an investigator, whether they're in Florida, New York, or in Oregon, they have to ask the FDA for permission to get our drug, and then we provide the drug. And every single time, we've seen a profound change in outcomes for these individuals' lives. The FDA's been witness to that as well. So, if we just back up 14 months ago, the FDA changed our phase III study design, in concert with us, of course, to streamline it so that we could have a very simple study to have a single arm, open label, to expedite the actual regulatory pathway.

Because as long as we can replicate what we've all seen in the real world, then this drug should be approved. And the FDA's been very clear about the need and the unmet need, in which we all know. No one wants to see someone who is suffering with cancer have to have hypoglycemia of this state and then pass away. So, the question is it approvable with a single-arm study? Absolutely, because that's exactly what the FDA wants, and because of this massive unmet need.

Debjit Chattopadhyay
Company Representative, Guggenheim

On the CHI topic, FDA is aligned with you guys, asking now for a pre-BLA meeting. Could you provide some more insights into what happened behind the scenes over there, and why did you choose to wait for the upLIFT study before scheduling that meeting, which I think is going to happen early next year?

Nevan Elam
Founder and CEO, Rezolute

Happy to do so. On the congenital side, to bring back some hard memories for you, Debjit, and for all of us, a year ago, we were very surprised with the placebo response that we saw in our sunRIZE study in phase III, which was completely a confounder. Fortunately, the FDA agreed with us last March. They recognized that our primary endpoint, which was finger stick, self-monitored blood glucose, that that endpoint itself was a confounder, and that human behavior from parents and caregivers can significantly influence what study results may look like. And fortunately, the FDA said, "We hear you. We understand. Can you provide us the CGM data?"

So, with those snapshots every couple of minutes, 24 hours a day, that detailed data was very When you mine that data, it's very compelling, we believe, what you see, which is a 50%-75% difference, at worst-case scenario, between placebo and each of the treatment arms. So, we provided 500 tables, all of the raw data to the agency over the summer. They reviewed that data, and then about a month ago, they came back and said, "We understand. We're not telling you the drug's approvable, but what we are telling you is you should move forward with your BLA process." And that is, we believe, very compelling because we believe that the agency recognizes that, one, the unmet need in this patient population, like tumor, is massive for the children and their families.

And two, we believe they see what we see, which is there's clearly strong signs of efficacy, and we all know the history of the drug. We've been treating children now for more than, again, three years. Some children have been on their maintenance dose every month now for an extended period of time. Even out of the sunRIZE study, where we have open-label extension, for some of the children, it's been several years. They take their monthly maintenance dose. Some of the children are completely managing their hypoglycemia purely by using our drug, ersodetug.

All of that body of evidence, and this is where we get to the point of responsible drug development, and when a sponsor and the agency work together, I think we're seeing movement now within FDA, recognizing this in rare disease, where when the evidence gives you an indication of what the path forward should be, we should take it. This is, I think, a perfect example of being able to do that. We're very emboldened, very emboldened now to be prepared to file a BLA next year for congenital. The latter part of your question of why would we wait to request the meeting is that this is an unusual setup.

I've been doing this for 30+ years, and I haven't quite ever had a fact pattern like this, where planning for success, if our tumor study is successful, and we walk into the agency and want to discuss the path forward from the regulatory landscape, what do we do for both indications? Clearly, it will be supportive on the tumor side all the way around in terms of mechanistic understanding of the drug. We want to file and get the congenital indication approved first. We want the PRV. But also, it's in the public interest not to delay the approvability for the tumor indication. We think it's going to be a really rich conversation with the agency the first part of next year.

Debjit Chattopadhyay
Company Representative, Guggenheim

Will you choose to wait for the minutes before you disclose the outcome of the meeting, or if it is completely unambiguous, you'll have a disclosure relatively soon?

Nevan Elam
Founder and CEO, Rezolute

Well, I think since it's football season, what I'd say is it will be a game-time decision in terms of depending upon the outcome of the meeting, and we've always viewed it that way. Sometimes, as you know by our history in the last couple years, it's very clear. When the agency told us, "Get rid of the placebo arm in your tumor study," we didn't wait for minutes. We announced. Similarly, we didn't wait earlier this year when we met with the agency, and they said, "Guys, we recognize that there is an issue with the placebo effect." We announced. We'll see. I can't tell you today.

Debjit Chattopadhyay
Company Representative, Guggenheim

Got it. One last question on the upLIFT study. As of now, you have seven out of eight who have responded. You need two more. Very unlikely upLIFT is not going to work. What is the best case that you want to take to the FDA, 56% or as close to 100% as possible?

Nevan Elam
Founder and CEO, Rezolute

Well, I think it is really interesting to note that the agency agreed with us to really lower the bar from what we saw and what we have all observed in our EAP, where we treated more than a dozen patients in the U.S. and in Europe, and over those last few years, the pretty remarkable change that patients have experienced and their ability to get out of the hospital, to control their hypoglycemia, to get back on their cancer therapies, and to resume normal life activities. Our objective is to make sure that we at least hit the endpoint, which is 50% of the patients need to have a 50% reduction in glucose infusion requirements. But, of course, we would expect and hope that we can do better. That is the endpoint.

Now, I think to the extent we do better than that and the results actually match what we have seen in the EAP, I think that will be very powerful, and I think it very much underscores what we like to call internally the sledgehammer effect of ersodetug being able to knock down refractory hypoglycemia. We have to hit the endpoint, first and foremost. Beyond that, I think it is all upside.

Debjit Chattopadhyay
Company Representative, Guggenheim

Got it. Sunil, you have been with Rezolute for about a year and a half at this point?

Sunil Karnawat
CCO, Rezolute

Yeah, about a year.

Debjit Chattopadhyay
Company Representative, Guggenheim

Obviously, you have had time to think about what the true epi looks like both for THI and CHI. Maybe we can start talking about what that number looks like for you guys, assuming ersodetug is broadly approved next year.

Sunil Karnawat
CCO, Rezolute

Yeah, sure. Thanks for the question, Debjit. I'll start with CHI first. In terms of CHI, when we looked at the claims analysis, we think that definitely there are 1,500 pediatric patients available right now that are diazoxide non-responsive. We also think that the patients that are actually responding to diazoxide, at least 40% should have a repeated hypoglycemia, and we think most of those patients will migrate to ersodetug upon launch. Right now, we are thinking for congenital, the total addressable market will be about 2,000 patients for that indication.

Debjit Chattopadhyay
Company Representative, Guggenheim

Let's talk about the THI numbers, and then I can—

Sunil Karnawat
CCO, Rezolute

Sure.

Debjit Chattopadhyay
Company Representative, Guggenheim

—get back into—

Sunil Karnawat
CCO, Rezolute

Yeah. For THI, I will break it down between the two indications, insulinoma and NICTH. We did the same work for insulinoma. We looked at the claims database, and we made sure that we are picking the patients that are having the specific ICD-10 code C25.4, repeated hypoglycemia, hospitalization, emergency visit as well as treated with the diazoxide and SSAs. When we looked at the data, what we find is that currently in the marketplace, there are about 2,500 patients that are having a repeated hypoglycemia, refractory hypoglycemia, along with the hospitalization. We think the TAM for insulinoma is about 2,500 patients in the market if we sort of launch today. For NICTH, we went through the similar exercise.

Now, for NICTH, there is no specific code, so we looked at the 16 tumor types that typically throw this IGF-2, and we looked at the hypoglycemia, and as you know, there is no treatment for this patient. Diazoxide doesn't work here. So we looked at the steroids, hospitalization, and we think there is about 1,500 patients in the marketplace right now as a prevalent population for NICTH. So if you sum it up, about 4,000 for tumor indication, addressable market, and about 2,000 for congenital. So about 6,000 total population for both the indications.

Debjit Chattopadhyay
Company Representative, Guggenheim

What are your assumptions right now for durability of, or duration of treatment?

Sunil Karnawat
CCO, Rezolute

Yeah. I think this is the one that we are assuming based on our EAP experience, that some patients are actually on the program for more than two years. insulinoma, we think that could have a little bit of a longer duration than NICTH, and the assumption is really based on the EAP because in real world, we really don't know how that looks in the claims database. We can only go with what we know from EAP experience.

Debjit Chattopadhyay
Company Representative, Guggenheim

If you can unpack that in from a durability of treatment, one of the pushbacks that we've sort of heard on this is, while it's taken a fairly long time for the upLIFT study to enroll, how many patients are truly available for therapy? In a real world, will this go in earlier? If it goes in earlier, what do you think about pricing?

Nevan Elam
Founder and CEO, Rezolute

Maybe I'll take the first part of that, if I could.

Debjit Chattopadhyay
Company Representative, Guggenheim

Sure.

Nevan Elam
Founder and CEO, Rezolute

Dr. K. A clinical study is a clinical study, and that's not reflective, and especially in ultra-rare disease, of what a patient population. I think our sunRIZE experience is very informative of needing to be careful. Even when you're extremely careful, you can still have confounders. In the upLIFT study for tumor, we wanted to make sure we enrolled the right patient population to really reflect the efficacy of the drug. But in any ultra-rare disease where you're studying less than 100 patients, that doesn't necessarily reflect what the overall patient population is, clearly. I think the work that Sunil and his team have done is fantastic because it's so much deeper, and this is something we couldn't do 20, 30, 40 years ago.

With machine learning, our ability to actually penetrate and understand down to the physician and where they are in Minnesota, in Iowa, in San Diego, and the number of patients that they are specifically seeing that meet our validated ideal patient, for example, for insulinoma, that we can now do. It is very, very powerful. We just met with a variety of physicians who treat these individuals last week, and they are all recognizing the unmet need and the number of patients that are out there. This is just typical rare disease, not reflective. With respect to pricing, I will let you comment on that.

Sunil Karnawat
CCO, Rezolute

Yeah. I mean, I think this is ultra-rare disease pricing, and as you know, this is going to be a weight-based indication. Naturally, as we price for CHI, you are going to see the reflection for the tumor, given that the tumor population is at least 2x to 3x of the weight of the CHI population. CHI, 1,500 patients, tumor, 4,000 patients. It is a super ultra-rare disease. If you look at the impact on the payer's budget, it is going to be minimal. You are going to have one or two patients per payer. We should be able to get the ultra-rare pricing for both tumor as well as for CHI, and again, it is going to be a linear scale from CHI to tumor.

Nevan Elam
Founder and CEO, Rezolute

When you add that all up, just to sum it up, we believe that our total addressable market opportunity is well north of $5 billion. That has It is a very compelling, we think, market opportunity.

Debjit Chattopadhyay
Company Representative, Guggenheim

Are there examples that you can use in the tumor setting which would support, call it a high 100,000, hundreds of thousands price point?

Sunil Karnawat
CCO, Rezolute

Yeah, I launched a product. I have been in this rare disease space for last almost 10, 15 years, and I was fortunate to launch a product at Ultragenyx for CRYSVITA, which follows very similar path as ersodetug. It started with the pediatric indication for XLH, and then over the time, it got expanded to add tumor indication. As you know, it was a weight-based dosing, very similar to what we have for ersodetug, and the tumor indication was definitely expensive because it was a linear pricing. So I can think of that as an analog where payers have definitely paid for both the indications.

Debjit Chattopadhyay
Company Representative, Guggenheim

Got it. Nevan, you sort of alluded to this, with machine learning, you can pinpoint exactly where these patients are. So talk about the commercial organization and what do you need to have in place for a successful launch?

Sunil Karnawat
CCO, Rezolute

Yeah, I will take that one. So it is pretty lean team, actually.

Nevan Elam
Founder and CEO, Rezolute

You better take that one.

Sunil Karnawat
CCO, Rezolute

Yeah. If we look at the population and where these patients are treated for congenital, it is a very concentrated audience. About 80 - 90 pediatric hospitals treat 80% of the patients, and about 500 pediatric endos. We can have a very targeted effort along with the machine learning, the insight we get. We can actually go to the institutions where the patients are. We think that a commercial team, a small commercial team in the field, 10 - 15 salespeople, should be able to get us there. Of course, we will have the supporting infrastructure to make sure that we have a patient support services, market access team, commercial operations, supporting these patient find activities, as well as getting the patient onto the reimbursed drug. So, fairly small commercial team for congenital indication.

We may have a separate team for tumor indication, given that it is treated by the adult endos versus the pediatric endos. Again, if you look at the insulinoma and NICTH, it is fairly concentrated. Insulinoma, 300 institutions, about 1,000 adult endos, treating about 60% of the patients. Same for NICTH. There is a very strong overlap between the two. As you know, this is a very severe condition. Nevan talked about that. Most of these patients are getting treated either at the academic medical center or at the National Cancer Institute. If you look at the 65 NCIs and 200 academic medical centers, majority of our patients.

Speaker 4

Off-label use, because we often get asked how much CIndU uptake will there be once CSU is approved?

Nevan Elam
Founder and CEO, Rezolute

Wow.

Speaker 4

That said.

Nevan Elam
Founder and CEO, Rezolute

God is now speaking to us.

Speaker 4

Like many diseases that have been underserved and undertreated, there is enormous unmet need—

Nevan Elam
Founder and CEO, Rezolute

How about we just pull the plug?

Speaker 4

—in CIndU, and specifically SD and ColdU.

Nevan Elam
Founder and CEO, Rezolute

Okay. Wow.

Debjit Chattopadhyay
Company Representative, Guggenheim

Well, apologies for that.

Nevan Elam
Founder and CEO, Rezolute

Should I address her question?

Debjit Chattopadhyay
Company Representative, Guggenheim

I have completely lost the train of thought.

Sunil Karnawat
CCO, Rezolute

I continue. I think you were talking about the commercial footprint, and the point I was making is that for congenital, it is a fairly concentrated market, and so is for tumor. We could have a separate sales team in the field to do the patient find and also the reimbursement support. Again, because these are very concentrated patient population as well as the doctor that we are going to be talking to them, we think that the commercial footprint will be very optimal in the marketplace. Something like as a rare disease company, we can launch the product because with the machine learning, we know exactly where the patients are, and we can talk to the HCPs.

Debjit Chattopadhyay
Company Representative, Guggenheim

Got it. The other thing is obviously the BLA submission timelines. Assuming that the FDA greenlights the submission in CHI, and upLIFT is positive, could you walk us through the cadence? Because obviously there's a PRV component associated with one and not the other.

Nevan Elam
Founder and CEO, Rezolute

We actually are planning, and Sunil ramps up his organization right now as we're preparing for success. We already know we have a pathway for the congenital indication, to your point, and we are planning to be in a position in the middle of next year to file a BLA. The question is exactly what will that cadence look like between the indications? If we take the conservative path, which is probably prudent, we would assume that we would look for a Q1 PDUFA date for congenital in 2028, then nine months or so later, a PDUFA date for the tumor indication under an sBLA. That's a lot for a small company with this massive market opportunity to launch sequentially in two indications with the same drug, and it's great.

Sunil, we have the time now where we're looking at the calendar, a little over a year away from potentially being in a position to launch. As a result, we're ramping up internally and doing everything that a commercial organization needs to do to make sure that our launch is successful. We're also emboldened not just by Sunil's experience. I mean, he's a master of launching drugs in rare disease with his experience in biotech, but we've also seen analogs of small companies in the last couple years that have done a great job of launching their drugs, which historically we haven't seen, if you go back 10 or 15 years. But in the last five years, there have been small companies that have had really successful launches in the rare disease space.

We're going to make sure that we're also following in their footsteps, and we'll be prepared.

Debjit Chattopadhyay
Company Representative, Guggenheim

Given the tumor indication is more of an end-of-life situation, why another nine months for that?

Nevan Elam
Founder and CEO, Rezolute

That's a great question, and we don't know the answer today. It's not until we engage with the agency, because we know the agency is keenly focused on the tumor indication and its unmet need I described. Maybe it'll be truncated, but we don't know. We don't know until we actually have the conversation with the agency. The traditional path is the path that we all know, is one indication gets approved, and then you have a supplemental BLA. There are instances within the last 20 years where drugs that have a massive unmet need, they're accelerated in terms of the timeline for an sBLA. But we'll see. Not until we engage with the agency, we just don't know.

Debjit Chattopadhyay
Company Representative, Guggenheim

Got it. Given where your balance sheet is, assuming a positive BLA meeting or pre-BLA meeting next year, where do you think the investments needs to be, and how are you positioned for that?

Nevan Elam
Founder and CEO, Rezolute

We are positioned, we're fortunate to still, with about $90 million in cash today, be in a very healthy position to operate the company and to grow as we need to. Clearly, we're not positioned to launch in two indications. So, we'll be thoughtful about how we address our balance sheet and our cash needs, and to make sure that we're prepared. I think with our story, I think there will be a significant investor interest in what we're doing. So, we're excited.

Debjit Chattopadhyay
Company Representative, Guggenheim

All right, we have exactly a minute left. You talked about a $5 billion potential TAM, but your market cap is sub $500 million. What's the disconnect between the TAM versus what the investor perception is?

Nevan Elam
Founder and CEO, Rezolute

I think there's several things that probably lead to the disconnect, and I think you're right about the disconnect. There are often dislocations in markets, and in particular in biotech, and we've all seen this over and over again, where a company's true value is not realized until finally the lights are fully on and everyone can see. We may be part of that. I think it's also fair to say that with the placebo effect that we saw in our sunRIZE study last year, which was a disappointment, we're still recovering from that. What you typically don't see is a company that has an event like that coming out of phase III recover in six months or nine months back to where we already are.

The only reason why is, I think, because we all know the drug, we believe, is powerful, and we have two indications. I think that disconnect will that gap will close.

Debjit Chattopadhyay
Company Representative, Guggenheim

Appreciate the time. Thank you so much, and looking forward to a productive 2026.